Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC585 in Progressive Fibrosing Interstitial Lung Disease
NCT05139719Phase 2Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of yifenidone in progressive fibrosing interstitial lung disease (PF-ILD), sponsored by Sunshine Lake Pharma. Started Feb 2023; status: recruiting.
02
Drugs
yifenidone
03
Conditions
progressive fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT05139719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139719.